What is the equity of ASKA Pharmaceutical Holdings Co this year?
ASKA Pharmaceutical Holdings Co has equity of 61.93 B JPY this year.
In 2024, ASKA Pharmaceutical Holdings Co's equity was 61.93 B JPY, a 26.67% increase from the 48.89 B JPY equity in the previous year.
ASKA Pharmaceutical Holdings Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ASKA Pharmaceutical Holdings Co's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating ASKA Pharmaceutical Holdings Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
ASKA Pharmaceutical Holdings Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in ASKA Pharmaceutical Holdings Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
ASKA Pharmaceutical Holdings Co has equity of 61.93 B JPY this year.
The equity of ASKA Pharmaceutical Holdings Co has increased/decreased by 26.67% increased compared to the previous year.
A high equity is advantageous for investors of ASKA Pharmaceutical Holdings Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of ASKA Pharmaceutical Holdings Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of ASKA Pharmaceutical Holdings Co can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of ASKA Pharmaceutical Holdings Co can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of ASKA Pharmaceutical Holdings Co include profits, dividend payments, capital increases, and acquisitions.
The equity of ASKA Pharmaceutical Holdings Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, ASKA Pharmaceutical Holdings Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, ASKA Pharmaceutical Holdings Co paid a dividend of 45 JPY . This corresponds to a dividend yield of about 2.11 %. For the coming 12 months, ASKA Pharmaceutical Holdings Co is expected to pay a dividend of 48.3 JPY.
The current dividend yield of ASKA Pharmaceutical Holdings Co is 2.11 %.
ASKA Pharmaceutical Holdings Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.
ASKA Pharmaceutical Holdings Co paid dividends every year for the past 12 years.
For the upcoming 12 months, dividends amounting to 48.3 JPY are expected. This corresponds to a dividend yield of 2.26 %.
ASKA Pharmaceutical Holdings Co is assigned to the 'Health' sector.
To receive the latest dividend of ASKA Pharmaceutical Holdings Co from 12/1/2024 amounting to 25 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.
The last dividend was paid out on 12/1/2024.
In the year 2023, ASKA Pharmaceutical Holdings Co distributed 28 JPY as dividends.
The dividends of ASKA Pharmaceutical Holdings Co are distributed in JPY.
Our stock analysis for ASKA Pharmaceutical Holdings Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ASKA Pharmaceutical Holdings Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.